LONDON (Thomson Financial) - CeNeS Pharmaceuticals PLC said it has completed preparations for the phase III trials of its lead programme, M6G, in the US. The company said the partnering process for M6G is ongoing and it expects to announce a licensing deal in 2008. CeNeS said it expects the deal terms will provide for an initial up front sum along with future royalties.
